pyrazines has been researched along with Carcinoma in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 2 (6.25) | 18.2507 |
| 2000's | 15 (46.88) | 29.6817 |
| 2010's | 13 (40.63) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, L; Chen, G; Chen, Y; Cheng, Y; Fan, Y; Fang, J; Guo, Q; Han, Z; Jiang, L; Li, J; Li, X; Liang, Z; Lu, S; Luo, X; Ma, R; Ren, Y; Shi, J; Su, W; Sun, S; Wang, L; Xu, H; Yang, N; Zhang, H; Zhou, J | 1 |
| Chiang, AK; Ho, DN; Hui, KF; Lam, BH; Tsao, SW | 1 |
| Chiang, AK; Hui, KF | 1 |
| Huang, XE; Ji, AJ; Ju, WZ; Liu, SL | 1 |
| Chiappetta, G; Di Maro, G; Jarzab, B; Masullo, M; Monaco, M; Oczko-Wojciechowska, M; Orlandella, FM; Salerno, P; Salvatore, G; Santoro, M; Thomas, G; Unger, K | 1 |
| Chen, L; Wang, Q; Yang, HS; Zhang, Y | 1 |
| François, RA; Hochwald, SN; Kaye, FJ; Maeng, K; Nawab, A; Zajac-Kaye, M | 1 |
| Bertoglio, J; Bréard, J; Mérino, D; Micheau, O; Ndozangue-Touriguine, O; Sebbagh, M | 1 |
| Bauer, S; Bode, B; Knuth, A; Liewen, H; Renner, C; Samaras, P; Stenner, F; Tchinda, J; Weber, A; Zweifel, M | 1 |
| Brattain, MG; Hauser, J; Hu, YP; Humphrey, LE; Li, W; Panasiewicz, M; Patil, SB | 1 |
| Brossart, P; Fröhlich, E; Wahl, R | 1 |
| Ames, E; Hallett, WH; Murphy, WJ | 1 |
| Carew, JS; Esquivel, JA; Giles, FJ; Huang, P; Kelly, K; Mahalingam, D; Medina, EC; Mita, AC; Mita, MM; Nawrocki, ST; Swords, R; Zhang, H | 1 |
| Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Bavi, P; Hussain, AR; Jehan, Z; Munkarah, A; Uddin, S | 1 |
| Anderson, KC; Buon, L; Charalambous, E; Chauhan, D; Clynes, M; Daskalaki, E; Hayden, PJ; Hideshima, T; Kotoula, V; McMillin, DW; Mitsiades, CS; Mitsiades, N; Munshi, NC; O'Gorman, P; Ooi, MG; Raje, NS; Richardson, PG | 1 |
| Breen, M; Chen, CS; Keller, ET; Kisseberth, WC; Lanigan, LG; Martin, CK; McCauley, LK; Murahari, S; Nadella, MV; Rosol, TJ; Shu, ST; Simmons, JK; Thudi, NK; Van Bokhoven, A; Werbeck, JL; Williams, C | 1 |
| Reid, EG | 1 |
| Arndt, T; Bartsch, DK; Brendel, C; Fischer, M; Greene, BH; Hinterseher, U; Hoffmann, S; Ramaswamy, A; Roth, S; Wunderlich, A | 1 |
| Bhalla, P; Budunova, I; Iwadate, K; Karseladze, A; Ugolkov, A; Yang, X; Yemelyanov, A | 1 |
| Bartsch, DK; Brendel, C; Greene, BH; Hinterseher, U; Hoffmann, S; Ramaswamy, A; Roth, S; Wunderlich, A | 1 |
| Benedetti, V; Cincinelli, R; Corna, E; De Cesare, M; Gatti, L; Perego, P; Zaffaroni, N; Zunino, F | 1 |
| Blasick, TM; Brown, RE; Lun, M; Siegelmann-Danieli, N; Zhang, PL | 1 |
| Braun, T; Carvalho, G; Castedo, M; Coquelle, A; Kroemer, G; Métivier, D; Mouhamad, S; Pequignot, MO; Vivet, S | 1 |
| Ann, DK; Boo, LM; Chen, Y; Chung, V; Liu, X; Nguyen, HV; Song, J; Yen, Y; Zhou, B; Zhu, L | 1 |
| Ain, KB; Fanourakis, G; Kotoula, V; McMillin, D; McMullan, C; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V; Tseleni-Balafouta, S | 1 |
| Adamo, L; Anastasi, G; Conticello, C; De Maria, R; Eramo, A; Giuffrida, D; Giuffrida, R; Gulisano, M; Iannolo, G; Memeo, L; Vicari, L; Zeuner, A | 1 |
| Delmore, JE; Hayden, P; Kotoula, V; McMillin, DW; McMullan, C; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V | 1 |
| Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H | 1 |
| Conrad, CA; Edwards, CL; Forman, A; Freedman, RS; Grothey, A; Grove, W; Hasenburg, A; Kavanagh, JJ; Kudelka, AP; Meyers, CA; Varma, D; Verschraegen, CF | 1 |
| Hayashi, K; Ito, R; Ono, S; Tahara, E; Yokozaki, H | 1 |
| Adams, J; Elliott, P; Frankel, A; Kerbel, RS; Man, S | 1 |
| Reynolds, TB; Yamada, S | 1 |
1 review(s) available for pyrazines and Carcinoma
| Article | Year |
|---|---|
Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies.
Topics: Boronic Acids; Bortezomib; Carcinoma; Epstein-Barr Virus Infections; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Herpesvirus 8, Human; Humans; Incidence; Lymphoma; Proteasome Inhibitors; Pyrazines; Sarcoma, Kaposi; Virus Latency; Virus Physiological Phenomena | 2011 |
4 trial(s) available for pyrazines and Carcinoma
| Article | Year |
|---|---|
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Topics: Carcinoma; Carcinoma, Non-Small-Cell Lung; Exons; Humans; Lung Neoplasms; Pyrazines; Triazines | 2021 |
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Maximum Tolerated Dose; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Carbamates; Carcinoma; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Dyspnea; Female; Humans; Hyponatremia; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Phlebitis; Pyrazines; Pyridines; Survival Rate; Treatment Outcome | 1998 |
Amiloride (MK-870), a new antikaluretic diuretic. Comparison to other antikaluretic diuretics in patients with liver disease and ascites.
Topics: Acid-Base Equilibrium; Amidines; Ascites; Autopsy; Carcinoma; Diuretics; Ethacrynic Acid; Humans; Hydrochlorothiazide; Hydrogen-Ion Concentration; Hyperkalemia; Liver Cirrhosis; Liver Neoplasms; Pyrazines; Spironolactone; Triamterene; Water-Electrolyte Balance | 1970 |
27 other study(ies) available for pyrazines and Carcinoma
| Article | Year |
|---|---|
Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Herpesvirus 4, Human; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Pyrazines; Reactive Oxygen Species; Signal Transduction; Tumor Burden; Virus Replication; Vorinostat | 2013 |
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Proliferation; Depsipeptides; DNA Damage; Endoplasmic Reticulum Stress; Enzyme Activation; Female; Fluoresceins; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyridines; Reactive Oxygen Species | 2014 |
Anti-proliferation effects and molecular mechanisms of action of tetramethypyrazine on human SGC-7901 gastric carcinoma cells.
Topics: Apoptosis; Blotting, Western; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; NF-kappa B; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Up-Regulation | 2014 |
Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Endoplasmic Reticulum Stress; Gene Knockdown Techniques; Humans; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Oxidation-Reduction; Protein Disulfide-Isomerases; Proteins; Pyrazines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Up-Regulation | 2014 |
Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells.
Topics: Animals; Apoptosis Regulatory Proteins; Caco-2 Cells; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; HCT116 Cells; HT29 Cells; Humans; Imidazoles; Mice; Mice, Nude; Piperazines; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Ribosomal Protein S6 Kinases, 70-kDa; RNA-Binding Proteins; Xenograft Model Antitumor Assays | 2015 |
Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Focal Adhesion Kinase 1; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neuroendocrine Tumors; Organic Chemicals; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Carcinoma; Cell Membrane Permeability; Colonic Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Mitochondria; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2008 |
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; Pyridines; Sorafenib; Thyroid Neoplasms | 2008 |
Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Signal Transduction; Tumor Cells, Cultured | 2008 |
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Iodides; Lovastatin; Neoplasm Metastasis; Oxides; Pyrazines; Sirolimus; Thymus Gland; Thyroid Neoplasms; Tretinoin | 2009 |
Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Cytotoxicity, Immunologic; Female; Humans; Immunotherapy, Adoptive; Killer Cells, Natural; Mice; Mice, SCID; Protease Inhibitors; Pyrazines; Receptors, Death Domain; RNA, Messenger; Xenograft Model Antitumor Assays | 2009 |
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Cell Survival; Chloroquine; Colonic Neoplasms; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; HT29 Cells; Humans; Hydroxamic Acids; Lysosomes; Mice; Mice, Inbred BALB C; Mice, Nude; Proteasome Endopeptidase Complex; Pyrazines; Superoxides; Ubiquitinated Proteins; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Enzyme Activation; Female; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Mitochondria; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Proteasome Inhibitors; Pyrazines; S-Phase Kinase-Associated Proteins; Tissue Array Analysis; Transplantation, Heterologous; Up-Regulation | 2009 |
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Survival; Humans; Imidazoles; Multiple Myeloma; Mutation, Missense; Neoplasms, Glandular and Epithelial; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Tumor Suppressor Protein p53 | 2009 |
Development of a brain metastatic canine prostate cancer cell line.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Brain Neoplasms; Carcinogenicity Tests; Carcinoma; Cell Division; Cell Line, Tumor; Dogs; Immunohistochemistry; Incidence; Injections, Subcutaneous; Keratin-18; Keratin-7; Keratin-8; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Connective Tissue; Parathyroid Hormone-Related Protein; Phenylbutyrates; Prostatic Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Spinal Cord Neoplasms; Subcutaneous Tissue; Transplantation, Heterologous | 2011 |
Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Papillary; Caspase 3; Cell Cycle Checkpoints; Cell Proliferation; Flow Cytometry; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thyroid Neoplasms; Tumor Cells, Cultured | 2012 |
Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Pyrazines; Receptors, Androgen; Receptors, Glucocorticoid; Transcription Factor CHOP; Transcriptional Activation; Tyramine | 2012 |
Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.
Topics: Antineoplastic Agents; Aurora Kinases; Benzazepines; Boronic Acids; Bortezomib; Carcinoma; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Indicators and Reagents; Protein Serine-Threonine Kinases; Pyrazines; Signal Transduction; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzothiazoles; Boronic Acids; Bortezomib; Carcinoma; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Neoplasm Proteins; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Toluene; Tumor Suppressor Protein p53 | 2012 |
Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Pamidronate; Piperazines; Pyrazines; Pyrimidines; ras Proteins; Sirolimus | 2004 |
Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma; Cell Cycle; Colonic Neoplasms; Cyclin B; Humans; Pyrazines; Transcription Factor RelA | 2006 |
SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; NF-kappa B; Oropharyngeal Neoplasms; Pyrazines; SUMO-1 Protein | 2006 |
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Medullary; Caspases; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Enzyme Inhibitors; Humans; Insulin-Like Growth Factor I; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins c-jun; Pyrazines; Thyroid Neoplasms; Tumor Suppressor Protein p53 | 2006 |
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Immunohistochemistry; Proteasome Inhibitors; Pyrazines; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Neoplasms; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Medullary; Cell Line, Tumor; Colorimetry; Doxorubicin; Genes, bcl-2; Humans; Membrane Potentials; Oncogene Protein v-akt; Protease Inhibitors; Pyrazines; RNA, Neoplasm; Tetrazolium Salts; Thiazoles; Thyroid Neoplasms; Transcription, Genetic | 2007 |
Effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (vesnarinone) on the growth of gastric cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Northern; Carcinoma; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Nucleus; Humans; Pyrazines; Quinolines; RNA, Messenger; Stomach Neoplasms; Time Factors; Tumor Cells, Cultured | 1999 |
Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Carcinoma; Caspase Inhibitors; Caspases; Cell Adhesion; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Neoplasm; Female; Humans; Male; Ovarian Neoplasms; Phosphorylation; Prostatic Neoplasms; Protease Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2000 |